 | • レポートコード：MRC2-11QY11365 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、131ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は慢性肝疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（化学療法薬、標的療法、ワクチン、抗ウイルス薬、免疫グロブリン、コルチコステロイド、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別慢性肝疾患治療薬の競争状況、市場シェア ・世界の慢性肝疾患治療薬市場：種類別市場規模 2015年-2020年（化学療法薬、標的療法、ワクチン、抗ウイルス薬、免疫グロブリン、コルチコステロイド、その他） ・世界の慢性肝疾患治療薬市場：種類別市場規模予測 2021年-2026年（化学療法薬、標的療法、ワクチン、抗ウイルス薬、免疫グロブリン、コルチコステロイド、その他） ・世界の慢性肝疾患治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界の慢性肝疾患治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米の慢性肝疾患治療薬市場分析：米国、カナダ ・ヨーロッパの慢性肝疾患治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの慢性肝疾患治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の慢性肝疾患治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの慢性肝疾患治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Astellas Pharma、Bristol-Myers Squibb、Gilead Sciences、GlaxoSmithKline、F. Hoffmann-La Roche、Merck、Novartis、Sanofi、Pfizer、Takeda Pharmaceutical、Bausch Health、Theratechnologies、Alnylam Pharmaceuticals、Protagonist Therapeutics、Dicerna Pharmaceuticals、Endo International、Provectus Biopharmaceuticals、MAX BioPharma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Chronic Liver Diseases Therapeutics Market
The global Chronic Liver Diseases Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chronic Liver Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chronic Liver Diseases Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chronic Liver Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chronic Liver Diseases Therapeutics market.
Global Chronic Liver Diseases Therapeutics Scope and Market Size
Chronic Liver Diseases Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Liver Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Chemotherapy Drugs
Targeted Therapy
Vaccines
Antiviral Drugs
Immunoglobulins
Corticosteroids
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on regional and country-level analysis, the Chronic Liver Diseases Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Chronic Liver Diseases Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Astellas Pharma
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
F. Hoffmann-La Roche
Merck
Novartis
Sanofi
Pfizer
Takeda Pharmaceutical
Bausch Health
Theratechnologies
Alnylam Pharmaceuticals
Protagonist Therapeutics
Dicerna Pharmaceuticals
Endo International
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Liver Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Chemotherapy Drugs
1.2.3 Targeted Therapy
1.2.4 Vaccines
1.2.5 Antiviral Drugs
1.2.6 Immunoglobulins
1.2.7 Corticosteroids
1.2.8 Others
1.3 Market by Application
1.3.1 Global Chronic Liver Diseases Therapeutics Market Share by Application: 2020 VS 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chronic Liver Diseases Therapeutics Market Perspective (2015-2026)
2.2 Global Chronic Liver Diseases Therapeutics Growth Trends by Regions
2.2.1 Chronic Liver Diseases Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Liver Diseases Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Liver Diseases Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Liver Diseases Therapeutics Players by Market Size
3.1.1 Global Top Chronic Liver Diseases Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Chronic Liver Diseases Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Chronic Liver Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chronic Liver Diseases Therapeutics Revenue
3.4 Global Chronic Liver Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Chronic Liver Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Liver Diseases Therapeutics Revenue in 2019
3.5 Key Players Chronic Liver Diseases Therapeutics Area Served
3.6 Key Players Chronic Liver Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Chronic Liver Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Liver Diseases Therapeutics Breakdown Data by Type (2015-2026)
4.1 Global Chronic Liver Diseases Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Type (2021-2026)
5 Chronic Liver Diseases Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Chronic Liver Diseases Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chronic Liver Diseases Therapeutics Market Size (2015-2026)
6.2 North America Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020)
6.3 North America Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020)
6.4 North America Chronic Liver Diseases Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Chronic Liver Diseases Therapeutics Market Size (2015-2026)
7.2 Europe Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020)
7.3 Europe Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020)
7.4 Europe Chronic Liver Diseases Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Chronic Liver Diseases Therapeutics Market Size (2015-2026)
8.2 China Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020)
8.3 China Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020)
8.4 China Chronic Liver Diseases Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Chronic Liver Diseases Therapeutics Market Size (2015-2026)
9.2 Japan Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020)
9.3 Japan Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020)
9.4 Japan Chronic Liver Diseases Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Chronic Liver Diseases Therapeutics Market Size (2015-2026)
10.2 Southeast Asia Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020)
10.3 Southeast Asia Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020)
10.4 Southeast Asia Chronic Liver Diseases Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Details
11.1.2 Astellas Pharma Business Overview
11.1.3 Astellas Pharma Chronic Liver Diseases Therapeutics Introduction
11.1.4 Astellas Pharma Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020))
11.1.5 Astellas Pharma Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Liver Diseases Therapeutics Introduction
11.3.4 Gilead Sciences Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.3.5 Gilead Sciences Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Chronic Liver Diseases Therapeutics Introduction
11.4.4 GlaxoSmithKline Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.4.5 GlaxoSmithKline Recent Development
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Details
11.5.2 F. Hoffmann-La Roche Business Overview
11.5.3 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Introduction
11.5.4 F. Hoffmann-La Roche Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.5.5 F. Hoffmann-La Roche Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Liver Diseases Therapeutics Introduction
11.6.4 Merck Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.6.5 Merck Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Chronic Liver Diseases Therapeutics Introduction
11.7.4 Novartis Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.7.5 Novartis Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Chronic Liver Diseases Therapeutics Introduction
11.8.4 Sanofi Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.8.5 Sanofi Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Chronic Liver Diseases Therapeutics Introduction
11.9.4 Pfizer Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.9.5 Pfizer Recent Development
11.10 Takeda Pharmaceutical
11.10.1 Takeda Pharmaceutical Company Details
11.10.2 Takeda Pharmaceutical Business Overview
11.10.3 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Introduction
11.10.4 Takeda Pharmaceutical Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
11.10.5 Takeda Pharmaceutical Recent Development
11.11 Bausch Health
10.11.1 Bausch Health Company Details
10.11.2 Bausch Health Business Overview
10.11.3 Bausch Health Chronic Liver Diseases Therapeutics Introduction
10.11.4 Bausch Health Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.11.5 Bausch Health Recent Development
11.12 Theratechnologies
10.12.1 Theratechnologies Company Details
10.12.2 Theratechnologies Business Overview
10.12.3 Theratechnologies Chronic Liver Diseases Therapeutics Introduction
10.12.4 Theratechnologies Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.12.5 Theratechnologies Recent Development
11.13 Alnylam Pharmaceuticals
10.13.1 Alnylam Pharmaceuticals Company Details
10.13.2 Alnylam Pharmaceuticals Business Overview
10.13.3 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Introduction
10.13.4 Alnylam Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.13.5 Alnylam Pharmaceuticals Recent Development
11.14 Protagonist Therapeutics
10.14.1 Protagonist Therapeutics Company Details
10.14.2 Protagonist Therapeutics Business Overview
10.14.3 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Introduction
10.14.4 Protagonist Therapeutics Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.14.5 Protagonist Therapeutics Recent Development
11.15 Dicerna Pharmaceuticals
10.15.1 Dicerna Pharmaceuticals Company Details
10.15.2 Dicerna Pharmaceuticals Business Overview
10.15.3 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Introduction
10.15.4 Dicerna Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.15.5 Dicerna Pharmaceuticals Recent Development
11.16 Endo International
10.16.1 Endo International Company Details
10.16.2 Endo International Business Overview
10.16.3 Endo International Chronic Liver Diseases Therapeutics Introduction
10.16.4 Endo International Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.16.5 Endo International Recent Development
11.17 Provectus Biopharmaceuticals
10.17.1 Provectus Biopharmaceuticals Company Details
10.17.2 Provectus Biopharmaceuticals Business Overview
10.17.3 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Introduction
10.17.4 Provectus Biopharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.17.5 Provectus Biopharmaceuticals Recent Development
11.18 MAX BioPharma
10.18.1 MAX BioPharma Company Details
10.18.2 MAX BioPharma Business Overview
10.18.3 MAX BioPharma Chronic Liver Diseases Therapeutics Introduction
10.18.4 MAX BioPharma Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020)
10.18.5 MAX BioPharma Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chronic Liver Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Chemotherapy Drugs
Table 4. Key Players of Targeted Therapy
Table 5. Key Players of Vaccines
Table 6. Key Players of Antiviral Drugs
Table 7. Key Players of Immunoglobulins
Table 8. Key Players of Corticosteroids
Table 9. Key Players of Others
Table 10. Global Chronic Liver Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Chronic Liver Diseases Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Chronic Liver Diseases Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Chronic Liver Diseases Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Chronic Liver Diseases Therapeutics Market Share by Regions (2021-2026)
Table 16. Chronic Liver Diseases Therapeutics Market Market Trends
Table 17. Chronic Liver Diseases Therapeutics Market Drivers
Table 18. Chronic Liver Diseases Therapeutics Market Challenges
Table 19. Chronic Liver Diseases Therapeutics Market Restraints
Table 20. Global Chronic Liver Diseases Therapeutics Revenue by Players (2015-2020) (US$ Million)
Table 21. Global Chronic Liver Diseases Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Chronic Liver Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2019)
Table 23. Global Chronic Liver Diseases Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Chronic Liver Diseases Therapeutics Product Solution and Service
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 28. Global Chronic Liver Diseases Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Chronic Liver Diseases Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 32. Global Chronic Liver Diseases Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 34. North America Chronic Liver Diseases Therapeutics Market Share by Type (2015-2020)
Table 35. North America Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 36. North America Chronic Liver Diseases Therapeutics Market Share by Application (2015-2020)
Table 37. North America Chronic Liver Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 38. North America Chronic Liver Diseases Therapeutics Market Share by Country (2015-2020)
Table 39. Europe Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 40. Europe Chronic Liver Diseases Therapeutics Market Share by Type (2015-2020)
Table 41. Europe Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 42. Europe Chronic Liver Diseases Therapeutics Market Share by Application (2015-2020)
Table 43. Europe Chronic Liver Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 44. Europe Chronic Liver Diseases Therapeutics Market Share by Country (2015-2020)
Table 45. China Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 46. China Chronic Liver Diseases Therapeutics Market Share by Type (2015-2020)
Table 47. China Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 48. China Chronic Liver Diseases Therapeutics Market Share by Application (2015-2020)
Table 49. China Chronic Liver Diseases Therapeutics Market Size by Region (US$ Million) (2015-2020)
Table 50. China Chronic Liver Diseases Therapeutics Market Share by Region (2015-2020)
Table 51. Japan Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 52. Japan Chronic Liver Diseases Therapeutics Market Share by Type (2015-2020)
Table 53. Japan Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 54. Japan Chronic Liver Diseases Therapeutics Market Share by Application (2015-2020)
Table 55. Japan Chronic Liver Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 56. Japan Chronic Liver Diseases Therapeutics Market Share by Country (2015-2020)
Table 57. Southeast Asia Chronic Liver Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 58. Southeast Asia Chronic Liver Diseases Therapeutics Market Share by Type (2015-2020)
Table 59. Southeast Asia Chronic Liver Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 60. Southeast Asia Chronic Liver Diseases Therapeutics Market Share by Application (2015-2020)
Table 61. Southeast Asia Chronic Liver Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 62. Southeast Asia Chronic Liver Diseases Therapeutics Market Share by Country (2015-2020)
Table 63. Astellas Pharma Company Details
Table 64. Astellas Pharma Business Overview
Table 65. Astellas Pharma Product
Table 66. Astellas Pharma Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 67. Astellas Pharma Recent Development
Table 68. Bristol-Myers Squibb Company Details
Table 69. Bristol-Myers Squibb Business Overview
Table 70. Bristol-Myers Squibb Product
Table 71. Bristol-Myers Squibb Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 72. Bristol-Myers Squibb Recent Development
Table 73. Gilead Sciences Company Details
Table 74. Gilead Sciences Business Overview
Table 75. Gilead Sciences Product
Table 76. Gilead Sciences Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 77. Gilead Sciences Recent Development
Table 78. GlaxoSmithKline Company Details
Table 79. GlaxoSmithKline Business Overview
Table 80. GlaxoSmithKline Product
Table 81. GlaxoSmithKline Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 82. GlaxoSmithKline Recent Development
Table 83. F. Hoffmann-La Roche Company Details
Table 84. F. Hoffmann-La Roche Business Overview
Table 85. F. Hoffmann-La Roche Product
Table 86. F. Hoffmann-La Roche Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 87. F. Hoffmann-La Roche Recent Development
Table 88. Merck Company Details
Table 89. Merck Business Overview
Table 90. Merck Product
Table 91. Merck Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 92. Merck Recent Development
Table 93. Novartis Company Details
Table 94. Novartis Business Overview
Table 95. Novartis Product
Table 96. Novartis Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 97. Novartis Recent Development
Table 98. Sanofi Business Overview
Table 99. Sanofi Product
Table 100. Sanofi Company Details
Table 101. Sanofi Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 102. Sanofi Recent Development
Table 103. Pfizer Company Details
Table 104. Pfizer Business Overview
Table 105. Pfizer Product
Table 106. Pfizer Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 107. Pfizer Recent Development
Table 108. Takeda Pharmaceutical Company Details
Table 109. Takeda Pharmaceutical Business Overview
Table 110. Takeda Pharmaceutical Product
Table 111. Takeda Pharmaceutical Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 112. Takeda Pharmaceutical Recent Development
Table 113. Bausch Health Company Details
Table 114. Bausch Health Business Overview
Table 115. Bausch Health Product
Table 116. Bausch Health Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 117. Bausch Health Recent Development
Table 118. Theratechnologies Company Details
Table 119. Theratechnologies Business Overview
Table 120. Theratechnologies Product
Table 121. Theratechnologies Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 122. Theratechnologies Recent Development
Table 123. Alnylam Pharmaceuticals Company Details
Table 124. Alnylam Pharmaceuticals Business Overview
Table 125. Alnylam Pharmaceuticals Product
Table 126. Alnylam Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 127. Alnylam Pharmaceuticals Recent Development
Table 128. Protagonist Therapeutics Company Details
Table 129. Protagonist Therapeutics Business Overview
Table 130. Protagonist Therapeutics Product
Table 131. Protagonist Therapeutics Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 132. Protagonist Therapeutics Recent Development
Table 133. Dicerna Pharmaceuticals Company Details
Table 134. Dicerna Pharmaceuticals Business Overview
Table 135. Dicerna Pharmaceuticals Product
Table 136. Dicerna Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 137. Dicerna Pharmaceuticals Recent Development
Table 138. Endo International Company Details
Table 139. Endo International Business Overview
Table 140. Endo International Product
Table 141. Endo International Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 142. Endo International Recent Development
Table 143. Provectus Biopharmaceuticals Company Details
Table 144. Provectus Biopharmaceuticals Business Overview
Table 145. Provectus Biopharmaceuticals Product
Table 146. Provectus Biopharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 147. Provectus Biopharmaceuticals Recent Development
Table 148. MAX BioPharma Company Details
Table 149. MAX BioPharma Business Overview
Table 150. MAX BioPharma Product
Table 151. MAX BioPharma Revenue in Chronic Liver Diseases Therapeutics Business (2015-2020) (US$ Million)
Table 152. MAX BioPharma Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Liver Diseases Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Drugs Features
Figure 3. Targeted Therapy Features
Figure 4. Vaccines Features
Figure 5. Antiviral Drugs Features
Figure 6. Immunoglobulins Features
Figure 7. Corticosteroids Features
Figure 8. Others Features
Figure 9. Global Chronic Liver Diseases Therapeutics Market Share by Application: 2020 VS 2026
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. Chronic Liver Diseases Therapeutics Report Years Considered
Figure 14. Global Chronic Liver Diseases Therapeutics Market Size (US$ Million), YoY Growth 2015-2026
Figure 15. Global Chronic Liver Diseases Therapeutics Market Share by Regions: 2020 VS 2026
Figure 16. Global Chronic Liver Diseases Therapeutics Market Share by Regions (2021-2026)
Figure 17. Global Chronic Liver Diseases Therapeutics Market Share by Players in 2019
Figure 18. Global Top Chronic Liver Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Chronic Liver Diseases Therapeutics Revenue in 2019
Figure 20. North America Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. United States Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Canada Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Europe Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Germany Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. France Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. U.K. Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Italy Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Russia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. Nordic Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Rest of Europe Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. China Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Japan Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. South Korea Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Southeast Asia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. India Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Australia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Rest of Asia-Pacific Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Latin America Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Mexico Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Brazil Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Turkey Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. Saudi Arabia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 45. UAE Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 46. Rest of Middle East & Africa Chronic Liver Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 47. Astellas Pharma Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 49. Gilead Sciences Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 50. GlaxoSmithKline Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 51. F. Hoffmann-La Roche Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 52. Merck Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 53. Novartis Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 54. Sanofi Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 55. Pfizer Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 56. Takeda Pharmaceutical Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 57. Bausch Health Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 58. Theratechnologies Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 59. Alnylam Pharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 60. Protagonist Therapeutics Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 61. Dicerna Pharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 62. Endo International Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 63. Provectus Biopharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 64. MAX BioPharma Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2015-2020)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
中枢神経系疾患治療薬の世界市場（～2026年） A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system Market Analysis and Insights: Global Drugs for Central Nervous System Diseases Market The global Drugs for Central Nervous System Diseases market size is projected to reac…- 慢性肺疾患治療の世界市場（～2026年） Lung disease is a very common medical condition that is present in almost every region of the world. Chronic lung diseases can be dangerous and if not treated properly can cause death. The chronic lung diseases cause uneasiness and complications in the respiratory system thus causing difficulty in r…
- 慢性疾患管理の世界市場（～2026年） Chronic Disease Management which was also known as enhanced primary care earlier is the ongoing care and support which help in managing the health care of patient suffering with chronic disease such as asthma, cancer, diabetes, cardiovascular diseases, stroke, etc. It also require visits and support…
- 希少性肺疾患治療の世界市場（～2026年） Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists. Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are e…
- 非アルコール性脂肪肝疾患治療薬の世界市場（～2026年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …